Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate the safety and CTL reaction of novel peptide vaccination for advanced renal cell carcinoma
Renal Cell Carcinoma
BIOLOGICAL: HLA-A02 restricted HIG2
Number of Participants with Adverse Events as a Measure of Safety and Number of Participants with Adverse Events as a Measure of Safety and Tolerability, hematological and non-hematological adverse event, 2 years
CTL reaction, 2 years
The purpose of this study is to evaluate the safety and CTL reaction of novel peptide vaccination for advanced renal cell carcinoma